NCT04661111 is a NA clinical trial of Hymovis® ONE (32 mg/4 ml) in Knee Osteoarthritis, sponsored by Fidia Farmaceutici s.p.a..

Who is sponsoring NCT04661111?

NCT04661111 is sponsored by Fidia Farmaceutici s.p.a..

What drugs are being tested in NCT04661111?

Interventions in NCT04661111: Hymovis® ONE (32 mg/4 ml).

What condition does NCT04661111 study?

NCT04661111 studies Knee Osteoarthritis.

Is NCT04661111 still recruiting?

NCT04661111 is currently completed. Last updated 10 December 2020.

Last reviewed 2020-12-10 · How we verify

NCT04661111

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Hymovis ONE® (32mg/4ml) Intrarticular Injection in Active Patients With Knee Overuse Syndrome

Completed NA Last updated 10 December 2020

What this trial tests

NA trial testing Hymovis® ONE (32 mg/4 ml) in Knee Osteoarthritis in 31 participants. Completed in 28 June 2018.

Timeline

13 June 2016

Primary endpoint
28 September 2017

28 June 2018

Quick facts

Lead sponsor	Fidia Farmaceutici s.p.a.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	13 June 2016
Primary completion	28 September 2017
Estimated completion	28 June 2018
Sites	1 location across Italy

Drugs / interventions tested

Hymovis® ONE (32 mg/4 ml)

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

Fidia Farmaceutici s.p.a. — full company profile →

Who can join

Adults 18 to 65, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy and safety of Hymovis® ONE (32 mg/4 ml) single intra-articular injection, in the management of pain caused by knee osteochondral lesions.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Adhesive hydrogels in osteoarthritis: from design to application.
Duan WL, Zhang LN, Bohara R, Martin-Saldaña S, et al · · 2023 · cited 46× · PMID 36710340 · DOI 10.1186/s40779-022-00439-3
New Viscoelastic Hydrogel Hymovis MO.RE. Single Intra-articular Injection for the Treatment of Knee Osteoarthritis in Sportsmen: Safety and Efficacy Study Results.
Bernetti A, Agostini F, Alviti F, Giordan N, et al · · 2021 · cited 34× · PMID 34122099 · DOI 10.3389/fphar.2021.673988
The osteochondral regeneration paradox: why biomimetic scaffolds are biologically superior but injectable systems dominate the clinic.
Gubert S, Moon H, Oliva N, Texidó R. · · 2026 · PMID 41767232 · DOI 10.1039/d5ra09529h

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other Fidia Farmaceutici s.p.a. trials

Trials by the same sponsor.

NCT06190028 — Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Gl · NA · terminated
NCT06108999 — Management of Acute and Chronic Wounds With Hyaluronic Acid · NA · recruiting
NCT06062771 — Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery · NA · completed
NCT06103812 — Evaluate Performance and Safety of Hyalo4 Skin in Acute and Chronic Wounds · unknown
NCT04757038 — An Open Label, Randomized-controlled Trial to Assess Efficacy Safety of HYALODISC With Physical Exercise Program · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04661111 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fidia Farmaceutici s.p.a.
Last refreshed: 10 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04661111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing